Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, cirrhosis, and hepatocellular carcinoma (HCC).
• The role of Hepatitis G virus (HGV) co-infection in HCV-related liver disease progression and treatment response remains unclear.

Purpose of the Study:

• To determine the prevalence of circulating HGV-RNA in patients with HCV-related chronic liver disease and healthy blood donors.
• To investigate the impact of HGV co-infection on disease severity and response to interferon therapy in HCV patients.

Main Methods:

• Detection of HGV-RNA in 117 HCV patients (classified as chronic hepatitis, liver cirrhosis, or HCC) and 200 healthy blood donors.
• Analysis of HCV genotypes and serological markers for Hepatitis B virus (HBV) in co-infected patients.
• Evaluation of interferon treatment response and sustained virological response in a subset of chronic active hepatitis patients.

Main Results:

• HGV-RNA was detected in 4.3% of HCV patients and 5% of blood donors, with a higher prevalence in chronic hepatitis cases.
• HGV co-infection was observed in 4 out of 5 patients positive for anti-HBs and anti-HBc, with no jaundice.
• Interferon therapy showed a 55.6% initial response rate, but only 22.2% achieved sustained response. Favorable factors included younger age, low HCV-RNA, and HCV genotype III/2a.
• HGV co-infection did not significantly alter clinical severity, disease progression, or interferon treatment outcomes.

Conclusions:

• The prevalence of HGV infection is low in both HCV patients and the general population.
• HGV co-infection does not appear to influence the clinical course or treatment efficacy of HCV-related liver disease.
• Younger age, low viral load, and specific HCV genotypes (III/2a) are associated with better interferon treatment outcomes.